Purpose Unlimited Inc. acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,501 shares of the medical research company’s stock, valued at approximately $698,000.
Several other hedge funds also recently made changes to their positions in the business. Tema Etfs LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth approximately $26,000. Los Angeles Capital Management LLC acquired a new stake in Charles River Laboratories International during the fourth quarter valued at approximately $42,000. Sfam LLC bought a new stake in Charles River Laboratories International during the fourth quarter worth approximately $43,000. Activest Wealth Management grew its position in Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after buying an additional 218 shares during the last quarter. Finally, Elyxium Wealth LLC acquired a new position in Charles River Laboratories International in the fourth quarter worth approximately $46,000. Institutional investors and hedge funds own 98.91% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on CRL shares. Mizuho set a $192.00 price objective on Charles River Laboratories International in a research report on Friday, May 8th. Weiss Ratings cut Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Royal Bank Of Canada began coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price on the stock. JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Monday, April 13th. Finally, CLSA upgraded Charles River Laboratories International from a “hold” rating to an “outperform” rating and increased their price target for the company from $167.00 to $219.00 in a research report on Friday, May 29th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $211.00.
Charles River Laboratories International Stock Up 0.1%
Shares of NYSE:CRL opened at $185.17 on Monday. The firm has a 50 day simple moving average of $174.82 and a 200 day simple moving average of $182.75. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $228.88. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The company has a market cap of $8.92 billion, a PE ratio of -49.25, a price-to-earnings-growth ratio of 2.12 and a beta of 1.46.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same period in the previous year, the company posted $2.34 EPS. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current year.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- 3 Inflation-Fighting Stocks Built for Higher Oil Prices
- 3 Biotech Firms With Major Potential Catalysts in the Coming Months
- Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally?
- 3 Small-Cap Stocks Getting a Russell 2000 Rebalance Boost
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
